The Pentostatin Plus Cyclophosphamide Nonmyeloablative Regimen Induces Durable Host T Cell Functional Deficits and Prevents Murine Marrow Allograft Rejection

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 620-631

  Mariotti, Jacopo ^a   Taylor, Justin ^a   Massey, Paul R ^a   Ryan, Kaitlyn ^a   Foley, Jason ^a   Buxhoeveden, Nicole ^a   Felizardo, Tania C ^a   Amarnath, Shoba ^a   Mossoba, Miriam E ^a   Fowler, Daniel H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Fludarabine; Immune depletion; Immune suppression; Mixed chimerism; Preparative regimen

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 2; PENTOSTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSE INCREASE; DRUG POTENTIATION; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HOST CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; NONMYELOABLATIVE CONDITIONING; SPLEEN CELL; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; PENTOSTATIN; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 79954593204     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.11.029     Document Type: Article

References (30)

1. Georges G.E., Storb R. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation. Int J Hematol 2003, 77:3-14.
2. Giralt S., Khouri I., Champlin R. Nonmyeloablative "mini transplants." Cancer Treat Res 1999, 101:97-108.
3. Robak T., Lech-Maranda E., Korycka A., et al. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006, 13:3165-3189.
4. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
5. Storb R., Yu C., Barnett T., et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999, 94:1131-1136.
6. Childs R.W., Clave E., Tisdale J., et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral blood progenitor cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999, 17:2044-2049.
7. Kuwatani M., Ikarashi Y., Mineishi S., et al. An irradiation-free nonmyeloablative bone marrow transplantation model: importance of the balance between donor T-cell number and the intensity of conditioning. Transplantation 2005, 80:1145-1152.
8. Mitchell B.S., Mejias E., Daddona P.E., et al. Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A 1978, 75:5011-5014.
9. Sauter C., Lamanna N., Weiss M.A. Pentostatin in chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol 2008, 4:1217-1222.
10. Giblett E.R., Anderson J.E., Cohen F., et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972, 2:1067-1069.
11. Spiers A.S., Parekh S.J., Bishop M.B. Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin). J Clin Oncol 1984, 2:1336-1342.
12. Bolanos-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005, 23:2661-2668.
13. Miller K.B., Roberts T.F., Chan G., et al. A novel reduced-intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant 2004, 33:881-889.
14. Pavletic S.Z., Bociek R.G., Foran J.M., et al. Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem cell transplantation. Transplantation 2003, 76:877-881.
15. Petrus M.J., Williams J.F., Eckhaus M.A., et al. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant 2000, 6:182-189.
16. Murphy W.J., Kumar V., Bennett M. Acute rejection of murine bone marrow allografts by natural killer cells and T cells: differences in kinetics and target antigens recognized. J Exp Med 1987, 166:1499-1509.
17. Vallera D.A., Taylor P.A., Sprent J., et al. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 1994, 57:249-256.
18. Jung U., Foley J.E., Erdmann A.A., et al. CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 2003, 102:3439-3446.
19. Adjei A.A., Dagnino L., Wong M.M., et al. Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine. Cancer Chemother Pharmacol 1992, 31:71-75.
20. Tedde A., Balis M.E., Ikehara S., et al. Animal model for immune dysfunction associated with adenosine deaminase deficiency. Proc Natl Acad Sci U S A 1980, 77:4899-4903.
21. Brown J.B., Lee G., Grimm G.R., et al. Therapeutic benefit of pentostatin in severe IL-10-/- colitis. Inflamm Bowel Dis 2008, 14:880-887.
22. Yamauchi T., Nowak B.J., Keating M.J., et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001, 7:3580-3589.
23. Johnston J.B., Verburg L., Shore T., et al. Combination therapy with nucleoside analogs and alkylating agents. Leukemia 1994, 8(Suppl 1):S140-S143.
24. Weiss M.A., Maslak P.G., Jurcic J.G., et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003, 21:1278-1284.
25. Avramis V.I., Plunkett W. Metabolic and therapeutic efficacy of 9-b-d-Arabinofuranosyl 1-2-fluoradenine against murine leukemia P388. Cancer Res 1982, 42:2587-2591.
26. Sirotnak F.M., Chello P.L., Dorick D.M., et al. Specificity of systems mediating transport of adenosine, 9-b-d-Arabinofuranosyl 1-2-fluoradenine, and other purine analogues in L1210 cells. Cancer Res 1983, 43:104-109.
27. Huang S., Apasov S., Koshiba M., et al. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997, 90:1600-1610.
28. Trotta P.P., Tedde A., Ikehara S., et al. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin. Cancer Res 1981, 41:2189-2196.
29. Mariotti J., Foley J., Ryan K., et al. Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood 2008, 112:4765-4775.
30. Erdmann A.A., Gao Z.G., Jung U., et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 2005, 105:4707-4714.